Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

    ... The cytidine nucleoside analogue and epigenetic modifier azacitidine is approved in the U.S. for the treatment of all ... to the World Health Organization classification. Benefits of azacitidine treatment of patients with AML with >30% blasts have also been ...

    Research Article last updated 07/20/2018 - 5:15pm.

  2. Azacitidine

    ... turned off, MDS cells and cancer cells can grow freely. Azacitidine is approved by the U.S. Food and Drug Administration (FDA) for ...

    Drug last updated 03/24/2016 - 12:32pm.

  3. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia

    ... and clinical activity of an oral formulation of azacitidine in patients with myelodysplastic syndromes (MDSs), ... AND METHODS: Patients received 1 cycle of subcutaneous (SC) azacitidine (75 mg/m2) on the first 7 days of cycle 1, followed by oral ...

    Research Article last updated 07/20/2018 - 5:14pm.

  4. Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes

    ... The efficacy and tolerance of azacitidine in higher-risk myelodysplasia with hypocellular ... the overall survival (OS) advantage demonstrated with azacitidine versus conventional care regimens (CCR). Baseline BM biopsies of ...

    Research Article last updated 07/20/2018 - 5:15pm.

  5. Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes

    ... aimed to directly compare the efficacy and safety of azacitidine and decitabine in patients with myelodysplastic ... to leukaemic transformation, and adverse outcomes between azacitidine and decitabine. To minimize the effects of treatment selection bias ...

    Research Article last updated 07/20/2018 - 5:15pm.

  6. Azacitidine in lower-risk myelodysplastic syndromes.

    ... Azacitidine is the first agent to significantly prolong overall survival ... (MDS). Here, we review currently available data on azacitidine treatment in lower-risk MDS. In a phase III study, a subset of ...

    Research Article last updated 07/20/2018 - 5:14pm.

  7. Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations.

    ... Azacitidine is recommended for patients with higher-risk ... to other therapies. However, standard treatment with azacitidine has not been optimized and many issues about the use of azacitidine ...

    Research Article last updated 07/20/2018 - 5:15pm.

  8. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes.

    ... Lenalidomide and azacitidine are active in MDS patients, and may complement each other by ... . A recent Phase I trial testing the lenalidomide and azacitidine combination yielded encouraging results; however, lenalidomide’s ...

    Research Article last updated 07/20/2018 - 5:14pm.

  9. Azacitidine in the management of patients with myelodysplastic syndromes.

    ... of irreversible DNA methlytransferase inhibitors such as azacitidine was investigated with promising outcomes in the treatment of MDS. Azacitidine was initially approved in the USA by the Food and Drug ... in the AZA-001 study of patients with higher-risk MDS. Azacitidine has demonstrated significant and clinically meaningful prolongation ...

    Research Article last updated 07/20/2018 - 5:15pm.

  10. Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents.

    ... a rationale for using hypomethylating agents such as azacitidine . Growing evidence suggests that azacitidine may reverse epigenetic gene silencing at specific genomic targets. ...

    Research Article last updated 07/20/2018 - 5:14pm.